Cargando…
Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy
Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, h...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401311/ https://www.ncbi.nlm.nih.gov/pubmed/34452081 http://dx.doi.org/10.3390/pharmaceutics13081120 |
_version_ | 1783745520577019904 |
---|---|
author | Tefas, Lucia Ruxandra Barbălată, Cristina Tefas, Cristian Tomuță, Ioan |
author_facet | Tefas, Lucia Ruxandra Barbălată, Cristina Tefas, Cristian Tomuță, Ioan |
author_sort | Tefas, Lucia Ruxandra |
collection | PubMed |
description | Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, has emerged as a promising new candidate for cancer therapy, with selective cytotoxicity against CSCs in various malignancies. Nanotechnology provides an efficient means of delivering Sali to tumors in view of reducing collateral damage to healthy tissues and enhancing the therapeutic outcome. This review offers an insight into the most recent advances in cancer therapy using Sali-based nanocarriers. |
format | Online Article Text |
id | pubmed-8401311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84013112021-08-29 Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy Tefas, Lucia Ruxandra Barbălată, Cristina Tefas, Cristian Tomuță, Ioan Pharmaceutics Review Cancer stem cells (CSCs) are reportedly responsible for the initiation and propagation of cancer. Since CSCs are highly resistant to conventional chemo- and radiotherapy, they are considered the main cause of cancer relapse and metastasis. Salinomycin (Sali), an anticoccidial polyether antibiotic, has emerged as a promising new candidate for cancer therapy, with selective cytotoxicity against CSCs in various malignancies. Nanotechnology provides an efficient means of delivering Sali to tumors in view of reducing collateral damage to healthy tissues and enhancing the therapeutic outcome. This review offers an insight into the most recent advances in cancer therapy using Sali-based nanocarriers. MDPI 2021-07-22 /pmc/articles/PMC8401311/ /pubmed/34452081 http://dx.doi.org/10.3390/pharmaceutics13081120 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tefas, Lucia Ruxandra Barbălată, Cristina Tefas, Cristian Tomuță, Ioan Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy |
title | Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy |
title_full | Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy |
title_fullStr | Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy |
title_full_unstemmed | Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy |
title_short | Salinomycin-Based Drug Delivery Systems: Overcoming the Hurdles in Cancer Therapy |
title_sort | salinomycin-based drug delivery systems: overcoming the hurdles in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401311/ https://www.ncbi.nlm.nih.gov/pubmed/34452081 http://dx.doi.org/10.3390/pharmaceutics13081120 |
work_keys_str_mv | AT tefasluciaruxandra salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy AT barbalatacristina salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy AT tefascristian salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy AT tomutaioan salinomycinbaseddrugdeliverysystemsovercomingthehurdlesincancertherapy |